All In Biotech

Drug Trial Radar · NCT00999167

A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HPN-100 for Maintaining Remission in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy

Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 189 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

189

Actual

Start

Dec 2009

Primary completion

Apr 2012

Study completion Apr 2012

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Oct 21, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 study of HPN-100 in subjects with hepatic encephalopathy (HE) consisting of an open label safety lead-in (Part A), followed by randomized, double-blind, placebo-controlled treatment (Part B).

Conditions

  • Cirrhosis
  • Hepatic Encephalopathy

Interventions

  • HPN-100Drug

    Part B: 6 mL BID for 16 weeks.

  • PlaceboDrug

    Part B: same as experimental arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: The Rate of AEs and Tolerability of HPN-100Time frame: Part A: 28 days
  2. Part B: Proportion of Subjects Who Exhibit an HE Episode, Defined as Either of the Following During the Treatment Phase: WH ≥2; WH Grade and Asterixis Grade Increase of 1 Each, if Baseline WH = 0Time frame: Part B: 112 Days

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University Medical Center, Division of Gastroenterology and Hepatology

    Palo Alto, California

  • Georgetown University Hospital

    Washington D.C., District of Columbia

  • University of Miami / Center for Liver Diseases

    Miami, Florida

  • Tampa General Hospital

    Tampa, Florida

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Tulane University Health Science Center

    New Orleans, Louisiana

  • University of Maryland

    Baltimore, Maryland

  • Henry Ford Hospital / Department of Gastroenterology

    Detroit, Michigan

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • Concorde Medical Group PLLC

    New York, New York

  • NYU Medical Center

    New York, New York

  • Mount Sinai Medical Center

    New York, New York

  • Columbia University Medical Center / Center for Liver Disease and Transplantation

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • New York Medical College / Westchester Medical Center

    Valhalla, New York

  • University of Cincinnati / Division of Digestive Diseases

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • The Digestive Disease Center at Vanderbilt

    Nashville, Tennessee

  • Methodist Dallas Medical Center

    Dallas, Texas

  • UT Southwestern Medical Center

    Dallas, Texas

  • Baylor College of Medicine-St. Luke's Episcopal Hospital

    Houston, Texas

  • University of Virginia Health System

    Charlottesville, Virginia

  • University of Wisconsin Hospital & Clinics

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.